Lymphotoxin α revisited: general features and implications in rheumatoid arthritis by Calmon-Hamaty, Flavia et al.
Introduction
Rheumatoid arthritis (RA) is a chronic inﬂ  ammatory 
disease aﬀ  ecting synovial joints. A hallmark of RA is the 
pseudotumoral expansion of ﬁ  broblast-like synoviocytes 
(FLSs), which invade and destroy the joint. Tumor 
necrosis factor-alpha (TNFα) plays a major role in pro-
mot  ing RA, and blocking this cytokine is eﬀ  ective for 
treating patients with RA [1]. However, a signiﬁ  cant 
number of patients do not respond or become resistant 
to anti-TNF therapies; approximately 50% of the patients 
still receive anti-TNFs 5 years after the start of treatment 
[2]. Th  e participation of other cytokines in RA has also 
been reported and could explain the absence of response 
to anti-TNFs. Often, patients treated with anti-TNFs 
show secondary eﬀ  ects such as recurrent infections [3]. 
Th   erefore, it is important to deﬁ  ne additional therapeutic 
strategies in order to better control synovial inﬂ  ammation 
and joint destruction observed in RA. Although lympho-
toxin alpha (LTα) has been associated with autoimmune 
and inﬂ  ammatory diseases and is the closest homolog to 
TNFα, few data pointing to a role for LTα in RA are 
available [4-10]. In this review, we aim to summarize the 
general features of LTα and what at present is known 
about its role in RA.
Lymphotoxin alpha in general
LTα, formerly known as TNFβ, was originally described 
in 1968 as a cytotoxic factor produced by T lymphocytes 
after antigenic or mitogenic stimulation [11]. Later on, in 
1984, human LTα was puriﬁ  ed from a B-lymphoblastoid 
cell line [12,13] and its structure was determined by 
classic protein-sequencing methods, making LTα the ﬁ  rst 
member of the TNF superfamily to be characterized [14]. 
TNFα was subsequently puriﬁ   ed, and sequence com-
parison and receptor competition experiments revealed 
that these two proteins were homologous [15,16]. Indeed, 
LTα is the closest homolog to TNFα.
LTα and TNFα are 30% homologous in their primary 
amino acid sequence, but of greater signiﬁ  cance is the 
observation that the regions of major sequence homology 
indicated a similarity in their tertiary and quaternary 
structures [15]. LTα is structurally similar to TNFα: LTα 
is a soluble homotrimer composed of 17-kDa monomers 
and binds to and signals speciﬁ  cally through TNF recep-
tors 1 and 2 (TNFR1 and TNFR2) to exert its biological 
activities.
Although LTα and TNFα have many similarities, there 
are some distinct molecular and biological diﬀ  erences 
[17,18]. Like TNFα, LTα binds with high aﬃ   nity  to 
TNFR1 and TNFR2 [19]. However, the N-terminus of 
LTα, unlike that of TNFα, resembles a traditional signal 
peptide, making its conversion to a soluble form 
extremely eﬃ   cient. Th  us, LTα is never found at the cell 
surface, a unique feature among the TNF superfamily 
members. LTα is anchored to the cell membrane only in 
association with membrane-bound LTβ, as LTαβ hetero-
trimers [20]. LTαβ is structurally distinct from LTα and 
comprises two membrane-anchored heterotrimers, the 
predominant LTα1β2 form and a minor LTα2β1 form, 
Abstract
Rheumatoid arthritis (RA) is a chronic infl  ammatory 
disease aff  ecting synovial joints. Therapies blocking 
tumor necrosis factor-alpha (TNFα) are now routinely 
used in the management of RA. However, a signifi  cant 
number of patients with RA do not respond or 
develop resistance to anti-TNF therapies, and the 
participation of other cytokines in RA pathogenesis 
has been reported as well. Lymphotoxin alpha (LTα) is 
the closest homolog to TNFα and has been implicated 
in infl  ammation and autoimmunity since its original 
description in 1968. In spite of that, little is known 
about the role of LTα in RA or the potential of blocking 
this cytokine as an alternative therapeutic approach. 
In this review, we aim to summarize the general 
features of LTα and what is currently known about its 
participation in RA.
© 2010 BioMed Central Ltd
Lymphotoxin α revisited: general features and 
implications in rheumatoid arthritis
Flavia Calmon-Hamaty1, Bernard Combe1-3, Michael Hahne1,4 and Jacques Morel*1-3
REVIEW
*Correspondence: j-morel@chu-montpellier.fr
1Institut de Génétique Moléculaire de Montpellier, 1919 route de Mende, CNRS 
UMR5535, Montpellier, France
Full list of author information is available at the end of the article
Calmon-Hamaty et al. Arthritis Research & Therapy 2011, 13:232 
http://arthritis-research.com/content/13/4/232
© 2011 BioMed Central Ltdboth of which interact with the LTβ receptor (LTβR) 
[18,21,22]. Besides binding to TNFR1 and TNFR2, LTα 
binds to HVEM (herpesvirus entry mediator), a receptor 
discovered as an entry route for herpes simplex virus, but 
this binding is relatively weak [23].
LTα is expressed by CD4+ T helper type 1 (Th  1)  cells, 
CD8+ cells, natural killer (NK) cells, B cells, and macro-
phages [18]. LTα has speciﬁ  c roles in the development 
and function of the immune system, mainly in lymphoid 
organ development, organization and maintenance of 
lymphoid microenvironments, host defense, and inﬂ  am-
mation [18]. However, most of the evidence pointing to 
these roles came from genetically deﬁ  cient mice and the 
relevance of LTα in humans is less clear. Moreover, these 
mice models make it diﬃ   cult to determine the relative 
role of LTα in these systems. Th   is is because the LTα gene 
is closely linked to the TNFα and LTβ genes and targeting 
the  LTα gene can lead to collateral damage to the 
neighboring genes [24]. Addition  ally, LTα could some-
how control the expression of TNFα and the absence of 
LTα could interfere with the production of this cytokine. 
In any case, although LTα was once considered to be 
redundant to TNFα, the fact that the same cell types 
express both LTα and TNFα and that knockout mice for 
either cytokines can manifest diﬀ  erent  phenotypes 
suggest that the two cytokines have overlapping and 
diﬀ  erent functions.
In regard to the development of secondary lymphoid 
organs, it was shown that mice deﬁ   cient in LTα are 
completely devoid of peripheral lymphoid tissues, such as 
Peyer patches (PP) [25]. It has been demonstrated that 
LTα mediates PP formation through TNFR1 because 
TNFR–/– mice either lack or have abnormal PP whereas 
TNFα–/– mice have normal PP [26].
Several studies suggested a role for LTα in host defense 
against certain infections. Mice deﬁ   cient in LTα are 
highly susceptible to Staphylococcus aureus infections 
[27]. Other studies showed the LTα requirement for 
granuloma formation and resistance to Mycobacterium, 
Leishmania, and Plasmodium infections in mice [28-31]. 
However, whether these functions are mediated by LTα, 
LTβ, or even TNFα is unclear. Th   e contribution of LTα to 
host defense was further challenged by recently generated 
LTα–/– mice showing intact TNFα production, which 
allows the evaluation of LTα alone, as opposed to the 
earlier generated LTα–/– mice that showed altered expres-
sion of TNFα [32].
LTα has been implicated in inﬂ   ammation since its 
initial description. LTα induces inﬂ  ammation  in vivo 
when expressed under the control of the rat insulin 
promoter (RIP) at the sites of transgene expression in the 
pancreas and kidney of RIPLT mice [33], and this occurs 
even in LTβ–/– mice [34], indicating that LTα alone 
induces inﬂ   ammation. Additional data suggesting a 
pro inﬂ   ammatory role for LTα derive from studies on 
experi  mental allergic encephalomyelitis (EAE) and show 
that myelin basic protein-speciﬁ  c T-cell clones secrete 
LTα [35] and that LTα–/– mice are resistant to 
inﬂ  ammation and clinical signs of EAE whereas LTβ–/– 
mice can still develop EAE [36]. Th   e mechanisms through 
which LTα promotes inﬂ  ammation and lymphoid organ 
develop ment  are still poorly understood. One possibility 
is the induc  tion of adhesion molecules in endothelial 
cells. In vitro studies showed that recombinant human 
LTα induces expression of intercellular adhesion 
molecule (ICAM) and E-selectin in human endothelial 
cells [37]. RIPLT mice overexpressing LTα exhibited a 
high expression of ICAM-1 and vascular cell adhesion 
molecule-1 in the vasculature of the inﬂ  amed pancreas 
and kidney independently of T or B cell-derived 
cytokines [38]. LTα could also contribute to inﬂ  ammation 
by the induction of chemokines. In this manner, LTα 
induces the expression of RANTES (regulated upon 
activation, normal T cell expressed and secreted) and 
monocyte chemoattractant protein-1 in a murine 
endothelial cell line [39]. Moreover, LTα contributes to 
lymphatic vessel functions in steady-state conditions and 
induces lymphangiogenesis in in  ﬂ  am  mation  through 
mechanisms yet to be characterized [40].
LTα is required for the diﬀ  erentiation of NK cells and 
plays a role in the recruitment and antitumor activity of 
mature NK cells [41-43]. When inoculated subcuta-
neously with syngeneic B16F10 melanoma cells, LTα–/– 
mice develop enhanced tumor growth and metastasis in 
comparison with wild-type littermates. Th  is was asso-
ciated with a lower number of NK cells and with slower 
migration of these cells from the bone marrow to 
peripheral organs [44]. Established, preclinical graft-
versus-host disease (GVHD) models showed that LTα 
contributes to the development of GVHD, the most 
frequent complication of allogeneic transplantation [45]. 
Naïve and alloreactive CD4+ T cells secrete soluble LTα 
after T-cell receptor stimulation. LTα participates in 
GVHD-mediated epithelial cell apoptosis, target organ 
damage, and mortality and this is mediated through 
TNFR1 signaling [45]. Th  ese  eﬀ  ects were not redundant 
to TNFα, as GVHD patients treated with TNFRFc, which 
cross-reacts with and blocks LTα, have outcomes diﬀ  er-
ent from those of patients treated with anti-TNFα mono-
clonal antibody, as do patients with a chronic auto-
immune disease such as RA [8].
Lymphotoxin alpha in rheumatoid arthritis
Th  e ﬁ  rst reports suggesting a role for LTα in RA came 
from an analysis in patients with RA by enzyme-linked 
immunosorbent assay (ELISA), reverse transcription-
polymerase chain reaction, and immunohistochemistry. 
It has been reported that LTα levels are elevated in the 
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comparison with the healthy controls or patients with 
osteoarthritis [6,46]. A relevant piece of evidence linking 
LTα to RA was provided by a case report describing an 
RA patient with no beneﬁ  cial clinical eﬀ  ect after therapy 
with inﬂ  iximab, a monoclonal antibody that speciﬁ  cally 
blocks TNFα. Interestingly, subsequent treatment of this 
patient with etanercept, a TNFR2-Fc fusion protein that 
also blocks LTα, resulted in clinical remission of the 
disease [8]. Th  e  diﬀ  erent ligand speciﬁ  cities of etanercept 
and inﬂ  iximab could account for the diﬀ  erent outcomes 
of this patient after both treatments. Increased LTα 
expression has been shown in the synovial tissue of this 
patient [8]. Th  ese data, together with the biological 
similari  ties between LTα and TNFα, suggest that resis-
tance to TNFα blockage may occur when TNFα is not the 
dominant inﬂ  ammatory cytokine and that LTα may play 
a role in the disease. An important advancement in the 
understanding of the participation of LTα in RA came 
from a study using the collagen-induced arthritis (CIA) 
mouse model, the most commonly used animal model 
for arthritis [47]. In this model, the blocking of LTα with 
a monoclonal antibody signiﬁ  cantly improved the disease 
[47]. Th   e main mechanism responsible for this improve-
ment in the CIA model appears not to be the blocking of 
soluble LTα but the depletion of LTα expressing Th  1  and 
Figure 1. Proposed model for the action of lymphotoxin alpha (LTα) in rheumatoid arthritis (RA) fi  broblast-like synoviocytes (FLSs). RA 
FLSs express all LTα receptors (TNFR1, TNFR2, and HVEM). TNFR1 contains a cytoplasmic death domain (DD). Although the specifi  c contribution 
of each receptor for LTα signaling remains to be clarifi  ed, RA FLSs are activated upon LTα binding through the phosphorylation of the mitogen-
activated protein kinases p38 and ERK1/2 and of the phosphatidylinositol 3-kinase (PI3K) Akt. Transcription factors such as nuclear factor-kappa-B 
(NF-κB), in turn, are activated. These events lead to cell responses involved in the pathogenesis of RA, such as proliferation, survival, and secretion 
of proinfl  ammatory cytokines, chemokines, and matrix metalloproteinases (MMPs). Based on [48]. ERK, extracellular signal-regulated kinase; HVEM, 
herpesvirus entry mediator; IL, interleukin; JNK, c-jun N-terminal kinase; RANTES, regulated upon activation, normal T cell expressed and secreted; 
TNFR, tumor necrosis factor receptor.
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study also binds to soluble LTα and inhibits its binding to 
a TNFR2.Ig in a competition ELISA [47]. An example of a 
dual functionality of an antagonist in RA is the well-
established monoclonal antibody inﬂ  ixi  mab, which binds 
speciﬁ  cally to TNFα. Besides blocking secreted TNFα, 
inﬂ   iximab can activate the complement cascade and 
deplete membrane-bound TNFα-expressing cells through 
a cytotoxic mechanism [18]. Recently, our group pro-
vided more evidence for a role of LTα in RA when we 
demon  strated that LTα can trigger activation (that is, 
proliferation and induction of an inﬂ  ammatory  and 
aggressive phenotype) of FLSs [48]. Th  e mechanisms 
through which LTα activates FLSs are depicted in 
Figure 1, in a proposed model for the action of LTα in RA 
FLSs. To better evaluate the role of LTα in RA, our group 
analyzed LTα levels in whole sera, plasma, and synovial 
ﬂ  uid of patients with RA, patients with osteoarthritis, 
and healthy controls. We were unable detect LTα reliably 
with the commercially available ELISA kits in these 
samples. However, this does not mean LTα is not 
expressed locally in joints of patients with RA. While it 
would be interesting to detect circu  lating LTα in synovial 
ﬂ   uid, it would be equally or even more important to 
obtain  in situ evidence of LTα expres  sion in arthritic 
tissue, where it might exert eﬀ   ects such as those we 
reported on synovial ﬁ  broblasts.
Conclusions
TNFα is known to play a crucial role in RA, but several 
other proinﬂ  ammatory cytokines have been identiﬁ  ed to 
contribute to the disease as well [49]. LTα can easily be 
placed in the context of the RA synovium as it is secreted 
by CD4+ Th  1 cells, CD8+ T cells, NK cells, and macro-
phages, cell types that are increased in the arthritic joint. 
Th   e fact that LTα activates RA FLSs and thus may contri-
bute to synovial hyperplasia suggests that LTα can also 
play a disease-promoting role in RA [48]. It will be 
important to further characterize the relevance of LTα in 
RA by detecting it in vivo in patients with RA.
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